Table 2. Clinical and molecular features of heterozygous (MV) iCJD cases analyzed.

Case ID Number	Gender	Age at Onset a	Duration b	Molecular Sub-classification	Brain Region c	PrPSc Type d	M129 (%) e
15	M	33	8	iCJD MV2	CC	2d	39 ± 9
16	F	30	12	iCJD MV2	CC	2d	38 ± 14
17	M	32	16	iCJD MV2	CC	2+1	46 ± 3
18	M	28	16	iCJD MV2	CC	2d	36 ± 5
19	F	27	32	iCJD MV2	CC	2d	66 ± 4
20	F	32	23	iCJD MV2	CC	2+1	39 ± 6

^aAge of onset in years.

^bDisease duration in months.

^cCC = cerebral cortex.

^dPrP^Sc typing according to the method of Parchi et al. [33].

^eMean percentage ± SD of PrP^Sc with M129.

There was no significant correlation of percentage PrP^Sc-M129 with iCJD type, age of onset, or disease duration (p>0.3).